Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?
Nearly 90% Discount To Astellas/Pfizer’s Xtandi
Executive Summary
Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.
You may also be interested in...
Zydus Cadila Strengthens Pipeline With 35 FDA Approvals
India’s Zydus Cadila is working on strengthening its pipeline with 35 product approvals from the FDA over the course of its most recent financial year. The company also filed for 22 new ANDAs during FY2021. And ahead of recently launching the world’s first biosimilar to Roche’s Kadcyla (trastuzumab emtansine) in India, the company reported significant growth in its domestic business.
Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount
Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy
Gilead Remdesivir Production: Partnering, Licensing Concerns And Beximco’s Plans
Gilead has opened up discussions with potential licensing partners, including leading Indian firms, to rapidly scale up supplies of remdesivir, the antiviral that has received FDA emergency use authorization to tackle COVID-19. Healthcare activists say past licensing models used by the US firm are flawed and unacceptable during a global health emergency.